Table 2 Correlation between MRS scores at different time points (weeks 1, 2, and ≥4) after initiation of IVIG therapy and the immunological parameters such as IL-33, T_reg cells, and PGE₂ at week 1. The values in the parenthesis denote statistical significance

From: Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy